Abstract
There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Current Neuropharmacology
Title: Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis
Volume: 9 Issue: 1
Author(s): Hideaki Kobayashi, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Mitsuhiko Yamada, Yoshimoto Sekine, Naohisa Uchimura, Masaomi Iyo, Norio Ozaki, Masanari Itokawa and Ichiro Sora
Affiliation:
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Abstract: There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Export Options
About this article
Cite this article as:
Kobayashi Hideaki, Ujike Hiroshi, Iwata Nakao, Inada Toshiya, Yamada Mitsuhiko, Sekine Yoshimoto, Uchimura Naohisa, Iyo Masaomi, Ozaki Norio, Itokawa Masanari and Sora Ichiro, Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017335
DOI https://dx.doi.org/10.2174/157015911795017335 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus
Current Diabetes Reviews The Effectiveness of Interventions to Address Health Inequalities During Pregnancy: A Review of Relevant Literature
Current Women`s Health Reviews In Vitro Elucidation of the Folding Intermediates and Aggregate Formation of Hemoglobin Induced by Acetonitrile: A Multispectroscopic Approach
Protein & Peptide Letters Potential Anti-Catabolic and Anabolic Properties of Strontium Ranelate
Current Molecular Pharmacology Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition
Current Neuropharmacology “Early” or Timely Discharge in Kangaroo Mother Care: Evidence and Experience
Current Women`s Health Reviews Update on the Use of Biologics in Lupus
Current Pharmaceutical Biotechnology In Silico Evaluation of Acetylation Mimics in the 27 Lysine Residues of Human Tau Protein
Current Alzheimer Research Anti-Inflammatory Activity of Novel 12-N-methylcytisine Derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: Future Directions for Stem Cell Banking and Therapy
Current Stem Cell Research & Therapy Chemokines SNPs in HIV-1+ Patients and Healthy Controls from Northeast Brazil: Association with Protection against HIV-1 Infection
Current HIV Research Editorial (Thematic Issue: Effective and Promising Treatments for Neurological Disorders and Cancer)
Current Pharmaceutical Design Identify Compounds' Target Against Alzheimer's Disease Based on In-Silico Approach
Current Alzheimer Research Synthesis and In Silico Molecular Docking Studies on Substituted Piperic Acid Derivatives as Inhibitors of Bacterial DNA Gyrase
Current Computer-Aided Drug Design Synthesis and Some Reactions of 1-aryl-4-acetyl-5-methyl-1,2,3-triazole Derivatives with Anticonvulsant Activity
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Oxidative Stress and Alzheimer Disease: Where Do We Stand?)
Current Alzheimer Research The Potential Interest of Topiramate in Addictions
Current Pharmaceutical Design Gold - Old Drug with New Potentials
Current Medicinal Chemistry